AQW-051AQW-051 also known as VQW-765 is an orally available, highly selective partial agonist of the alpha-7 nicotinic receptor (nAChR) developed by Novartis as a central nervous system agent aimed at improving cognitive function in disorders such as schizophrenia and Alzheimer's disease, and for reducing L-Dopa–induced… Read from the Drugbox of the Wikipedia article AQW-051, revision 1358175176.

Property

Value

Formula

C19H22N2O, 294.40 g/mol

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.